INZY vs. XOMA, ELYM, RAPT, XBIT, VSTM, XERS, CTMX, ENTA, AKBA, and NKTR
Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include XOMA (XOMA), Eliem Therapeutics (ELYM), RAPT Therapeutics (RAPT), XBiotech (XBIT), Verastem (VSTM), Xeris Biopharma (XERS), CytomX Therapeutics (CTMX), Enanta Pharmaceuticals (ENTA), Akebia Therapeutics (AKBA), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry.
XOMA (NASDAQ:XOMA) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Inozyme Pharma has a net margin of 0.00% compared to Inozyme Pharma's net margin of -886.91%. Inozyme Pharma's return on equity of -25.17% beat XOMA's return on equity.
XOMA has higher revenue and earnings than Inozyme Pharma. XOMA is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
XOMA received 395 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 81.40% of users gave Inozyme Pharma an outperform vote while only 65.95% of users gave XOMA an outperform vote.
In the previous week, Inozyme Pharma had 17 more articles in the media than XOMA. MarketBeat recorded 22 mentions for Inozyme Pharma and 5 mentions for XOMA. Inozyme Pharma's average media sentiment score of 0.18 beat XOMA's score of 0.14 indicating that XOMA is being referred to more favorably in the media.
XOMA has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.
95.9% of XOMA shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 7.2% of XOMA shares are owned by insiders. Comparatively, 11.9% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
XOMA presently has a consensus price target of $57.00, indicating a potential upside of 132.94%. Inozyme Pharma has a consensus price target of $17.00, indicating a potential upside of 280.31%. Given XOMA's higher possible upside, analysts plainly believe Inozyme Pharma is more favorable than XOMA.
Summary
Inozyme Pharma beats XOMA on 9 of the 16 factors compared between the two stocks.
Get Inozyme Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inozyme Pharma Competitors List
Related Companies and Tools
